retatrutide approval status 2025 retatrutide fda approval Trial of next-gen weight-loss drug brings it one step closer to Retatrutide Weight Loss Results:Trial Data

If you find that your current pen-based system is too rigid for your needs, we encourage you to take our free assessment quiz to explore more flexible, medically supervised options

The direct recording of ARNA with intrapelvic injections was performed as described previously [24, 26, 34, 35]

All authors in this study read and agreed the final manuscript

In STEP-1 (Wilding et al., NEJM 2021), 68 weeks of once-weekly 2.4 mg semaglutide plus lifestyle intervention produced a mean body-weight reduction of about 15%, versus about 2.4% with placebo a large, clinically meaningful, well-replicated effect

Results: Average ~15% body weight loss (based on STEP trials)